PEPTIDE: CJC-1295

CJC-1295 is not growth hormone. It is a growth hormone-releasing hormone (GHRH) analog, a synthetic 29-amino acid peptide that signals your pituitary somatotrophs to synthesise and release endogenous GH. The distinction matters: exogenous HGH bypasses every feedback loop your hypothalamic-pituitary axis uses to regulate output. CJC-1295 works within those loops.

The engineering is specific. Four amino acid substitutions (D-Alanine at position 2, Glutamine at 8, Alanine at 15, Leucine at 27) make the molecule resistant to dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades native GHRH within minutes. The result: a peptide that survives long enough to produce a clinically meaningful GH pulse.

The signalling cascade is straightforward: CJC-1295 binds GHRH receptors on pituitary somatotrophs, activating Gs protein, which triggers adenylyl cyclase, raising intracellular cAMP, activating protein kinase A, and initiating GH gene transcription and vesicle release.

Why This Matters

• Preserved feedback: Your somatostatin brake still works. GH output is amplified, not unregulated.

• Pulsatile release: Natural GH rhythms are maintained (particularly with the no-DAC version), unlike the flat pharmacokinetic profile of injected HGH.

• Dose-response ceiling: The pituitary has a finite secretory capacity. You cannot overdose into supraphysiological territory as easily as with exogenous GH.

This is the critical formulation fork. Both versions share the same 29-amino acid core, but the DAC (Drug Affinity Complex) version adds a maleimidoproprionic acid moiety that covalently binds serum albumin after injection. The pharmacokinetic consequences are dramatic.

Modified GRF 1-29 (No DAC)

• Half-life: approximately 30 minutes

• Produces discrete GH pulses that mimic natural secretion

• Requires daily injection (typically bedtime)

• Lower risk of receptor desensitisation

• Preferred for preserving natural GH pulsatility

CJC-1295 with DAC

• Half-life: 6-8 days (albumin-bound depot)

• Provides continuous GHRH stimulation

• Once-weekly dosing (1-2 mg)

• Higher risk of "GH bleed" and receptor downregulation

• Creates a sustained anabolic environment but at the cost of physiological rhythm

The "GH bleed" phenomenon is the core trade-off: continuous stimulation means the pituitary never fully rests between pulses. Over time, this can blunt receptor sensitivity, reduce peak GH amplitude, and produce a flat rather than pulsatile GH profile. Most research-focused protocols favour Modified GRF 1-29 for this reason.